MikroScore
New papers, curated and contextualized

Latest Research of the Week (2026-06-13)

Resveratrol with umbrella review, Omega-3 with network meta-analysis on vascular function, curcumin with two meta-analyses, and creatine in new chemo-cognition trial.

Published: 13/06/2026 resveratrolomega-3curcumincoq10kreatinurolithin-a

Latest Research of the Week (2026-06-13)

Quick Summary

The strongest signals this week come from resveratrol, omega-3, and curcumin — all three with new meta-analyses or review articles that consolidate existing evidence. Plus a methodologically interesting CoQ10 pilot trial in mitochondrial disease and a notable trial registration for creatine, showing that the supplement is increasingly taken seriously in clinical contexts beyond sports.

Most worth reviewing:

  • Resveratrol: Umbrella review + meta-analysis on blood sugar and lipid profile in type 2 diabetes
  • Omega-3: Network meta-analysis on nutraceutical effects on endothelial function
  • Curcumin: Two new meta-analyses (BPH and periodontitis)
  • CoQ10: Open pilot trial of a CoQ10-based food for special medical purposes in mitochondrial disease
  • Creatine: Phase 3 trial on cognitive health during chemotherapy

Most Interesting Signals This Week

Resveratrol

The most striking paper this week is an umbrella review with meta-analysis specifically examining the effects of resveratrol on glycemic markers and lipid profiles in type 2 diabetes. Methodologically, this is a step above individual meta-analyses — a review spanning multiple existing reviews.

But here’s where it gets interesting: The result is rather disappointing. Across 10 evaluated meta-analyses, the authors found no significant effect of resveratrol on fasting blood glucose, HbA1c, insulin, HOMA-IR, HDL, triglycerides, or total cholesterol in type 2 diabetics. Only LDL-C reduction was statistically significant, and insulin reduction appeared only in particularly large samples (n≥500). Heterogeneity was consistently high.

The authors’ conclusion is clear: Resveratrol cannot currently be regarded as an effective supplement for diabetes therapy.

Relevant Paper

MikroScore Commentary

For those who have relied on resveratrol for blood sugar and blood lipids: This umbrella review significantly dampens expectations. The “red wine molecule” remains mechanistically fascinating — but the clinical evidence on metabolic endpoints doesn’t hold up to scrutiny across 10 meta-analyses. We’ve updated our resveratrol dossier accordingly.

→ Related dossier: /en/ingredients/resveratrol

Omega-3

A network meta-analysis this week compares various nutraceuticals for their effect on endothelial function (measured as flow-mediated dilation / FMD) in patients with cardiovascular disease or hypertension. The key point: Omega-3 is not viewed in isolation, but in direct comparison with other substances.

The result is surprising: Omega-3 did improve FMD (MD: 1.83), but lagged far behind magnesium (MD: 8.17; high certainty of evidence) and vitamin D3 (MD: 7.84; high certainty of evidence). The certainty of evidence for the omega-3 effect was rated “very low” — meaning we can’t even be sure the effect is real.

Relevant Papers

New Trials

MikroScore Commentary

If you’re taking omega-3 for vascular function, contextualize this here: The effect on endothelial function may exist, but is weak and uncertain. If you want to specifically improve vascular health, magnesium or vitamin D3 are far superior by this analysis. This doesn’t change the strong omega-3 evidence for triglycerides and cardiovascular risk reduction — but it tempers claims about vascular protection. We’ve updated our omega-3 dossier accordingly.

→ Related dossier: /en/ingredients/omega-3

Curcumin

Curcumin remains a regular in the weekly review — and this week brings two new meta-analyses. One examines curcumin in benign prostatic hyperplasia, the other as a local application in periodontitis (adjunctive to scaling/root planing). Both are somewhat niche topics, but methodologically sound studies.

Relevant Papers

MikroScore Commentary

Both papers expand the curcumin picture in secondary indications. For the main dossier, more supplementary than directional.

→ Related dossier: /en/ingredients/curcumin

CoQ10

An open-label pilot trial examined a CoQ10-based food for special medical purposes in patients with mitochondrial disease. Small study, but in an area where few alternatives exist and every trial counts.

Relevant Paper

MikroScore Commentary

Of limited relevance for general supplement assessment, but a useful data point for the mitochondrial disease watchlist.

→ Related dossier: /en/ingredients/coq10

Creatine

The most interesting creatine signal this week isn’t a paper, but a trial registration: A phase 3 study wants to investigate whether creatine can protect cognitive health in breast cancer patients during and after chemotherapy. This is notable because it definitively moves creatine beyond the sports-only sphere.

New Trial

MikroScore Commentary

Results won’t come for at least 1–2 years, but the fact that a phase 3 trial was registered shows that creatine is increasingly taken seriously as a cognitive intervention.

→ Related dossier: /en/ingredients/kreatin

Trials on the Watchlist

Transparency Notice

This page is an editorial weekly review of new research findings. It does not replace individual assessment of an ingredient and makes no authorized health claims under EU regulations.